CStone Pharmaceuticals-B (02616) has announced that The Stock Exchange of Hong Kong has confirmed that Ms. Ni Weicong, the Joint Company Secretary, meets the qualifications under Rule 3.28 of the Listing Rules to serve as the Company Secretary following the expiry of her exemption on January 17, 2026. Consequently, Ms. Weng Meiyi has resigned from her position as Joint Company Secretary, effective February 6, 2026. Following Ms. Weng's resignation, Ms. Ni continues to serve as the sole Company Secretary of the company. Subsequent to her resignation as Joint Company Secretary, Ms. Weng has also resigned from her role as the Authorized Representative of the company under Rule 3.05 of the Listing Rules. Ms. Ni has been appointed as the Authorized Representative, replacing Ms. Weng, effective February 6, 2026. Dr. Yang Jianxin, an Executive Director of the company, remains as the other Authorized Representative. Ms. Weng will continue to serve as the company's authorized agent in Hong Kong for the service of legal process under Part 16 of the Companies Ordinance (Chapter 622 of the Laws of Hong Kong) and for receiving legal process and notices in Hong Kong on behalf of the company under Rule 19.05(2) of the Listing Rules.